|
ABHD10 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.96900000537914E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.17529999954513E-07 |
| Normal-vs-Stage2 |
4.827000E-01 |
| Normal-vs-Stage3 |
8.94910001658644E-09 |
| Normal-vs-Stage4 |
3.85450005246923E-10 |
| Stage1-vs-Stage2 |
6.44039999999624E-05 |
| Stage1-vs-Stage3 |
1.162010E-01 |
| Stage1-vs-Stage4 |
3.075700E-03 |
| Stage2-vs-Stage3 |
3.30429999995108E-06 |
| Stage2-vs-Stage4 |
3.92390000047982E-07 |
| Stage3-vs-Stage4 |
2.095800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.35940197671425E-11 |
| Normal-vs-AfricanAmerican |
7.419200E-03 |
| Normal-vs-Asian |
2.86569999952135E-07 |
| Caucasian-vs-AfricanAmerican |
2.703600E-01 |
| Caucasian-vs-Asian |
8.824200E-01 |
| AfricanAmerican-vs-Asian |
4.452200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.59880000016877E-07 |
| Normal-vs-Female |
3.16009999945521E-07 |
| Male-vs-Female |
4.849200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.30759997169139E-09 |
| Normal-vs-Age(41-60Yrs) |
3.98290000003243E-06 |
| Normal-vs-Age(61-80Yrs) |
4.166100E-04 |
| Normal-vs-Age(81-100Yrs) |
1.976260E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.507800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.444400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.727200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.398200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.608000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.646400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.93760000000154E-06 |
| Classical-VS-Follicular |
2.91110000549821E-08 |
| Classical-VS-Other |
7.649400E-01 |
| Classical-VS-Normal |
9.5875996031225E-10 |
| Tall-VS-Follicular |
1.64923630308067E-12 |
| Tall-VS-Other |
4.693600E-02 |
| Tall-VS-Normal |
1.84408044390239E-13 |
| Follicular-VS-Other |
4.093900E-02 |
| Follicular-VS-Normal |
5.456400E-01 |
| Other-VS-Normal |
1.039790E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.228700E-04 |
| Normal-vs-N1 |
1.01851860279112E-12 |
| N0-vs-N1 |
3.60599999860156E-08 |
|
|
